TSX runs higher on rate cut expectations
MIAMI - InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard Prime carotid stent system, announced Thursday the appointment of Raymond W. Cohen to its Board of Directors.
Cohen brings over 40 years of leadership experience in medical technology, most recently serving as CEO and co-founder of Axonics, Inc., which he led through its $3.7 billion acquisition by Boston Scientific in November 2024. Axonics was recognized as the fastest-growing company in the Americas by Deloitte and the Financial Times in 2021.
Until May 2025, Cohen served as Chairman of SoniVie Ltd., a clinical-stage company focused on hypertension treatment devices, until its $600 million acquisition by Boston Scientific. He currently holds board positions at Kestra Medical (NASDAQ:KMTS), which has a market capitalization of approximately $856 million and maintains a strong financial health score according to InvestingPro analysis, Spectrum Vascular Inc., and serves as Chairman of Nalu Medical and Vice Chairman of Tulavi, Inc.
The appointment comes after InspireMD recently received PMA approval for its CGuard Prime carotid stent system and is now focusing on commercial launch. According to InvestingPro data, Kestra Medical, where Cohen serves as a board member, has demonstrated impressive revenue growth of 115% over the last twelve months, though analysts currently maintain a cautious outlook. For deeper insights into medical technology companies and their growth metrics, investors can access comprehensive Pro Research Reports covering over 1,400 US equities on InvestingPro.
"The CGuard Prime stent system represents a true best-in-class innovation," Cohen said in the press release statement. "The Company’s singular focus, entrepreneurial agility, and deep clinical commitment uniquely positions it to penetrate and lead the U.S. carotid stent market."
InspireMD’s CGuard technology utilizes proprietary MicroNet mesh technology for carotid stenting procedures aimed at stroke prevention.
Marvin Slosman, Chief Executive Officer of InspireMD, stated that Cohen’s "operational acumen, strategic vision, and experience driving transformative growth brings a unique perspective" as the company executes its commercial launch strategy.
In other recent news, Kestra Medical Technologies reported strong financial results for the fourth quarter of fiscal year 2025. The company achieved a total revenue of $17.2 million, representing a 71% increase compared to the previous year. This performance surpassed both Stifel and consensus estimates of $15.7 million. Despite a negative earnings per share of -2.21, the revenue growth was driven by a 43% increase in ASSURE prescription volume and enhancements in revenue cycle management. Piper Sandler reiterated its Overweight rating on the company, with a price target of $27.00, while Stifel maintained its Buy rating and a $28.00 price target. Both firms highlighted the strong sales and gross margins, although operating expenses were higher than anticipated. These developments reflect the company’s robust performance and positive outlook from analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.